Maternal serum CA-125 level is elevated in severe preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biochemistry

Background:

• Pre-eclampsia is a serious pregnancy complication characterized by high blood pressure.
• Cancer antigen-125 (CA-125) is a protein that can be elevated in various conditions, including some pregnancy complications.
• The relationship between CA-125 levels and the severity of pre-eclampsia requires further elucidation.

Purpose of the Study:

• To investigate the association between serum CA-125 concentrations and the severity of pre-eclampsia.
• To determine if CA-125 levels can serve as a biomarker for pre-eclampsia severity.

Main Methods:

• A cohort of 91 pregnant females was evaluated, including those with severe pre-eclampsia (n=34), mild pre-eclampsia (n=24), and healthy pregnancies (n=31).
• Serum CA-125 levels were measured in all participants.
• Statistical analysis was performed to compare CA-125 levels across groups and correlate them with clinical parameters.

Main Results:

• Serum CA-125 levels were significantly elevated in the severe pre-eclampsia group compared to mild pre-eclampsia and control groups (p<0.05).
• No significant difference in CA-125 levels was found between the mild pre-eclampsia and control groups.
• CA-125 levels positively correlated with proteinuria, systolic blood pressure, and diastolic blood pressure.
• CA-125 levels negatively correlated with birth weight and gestational age at birth.

Conclusions:

• Elevated serum CA-125 levels are associated with severe pre-eclampsia.
• Increased CA-125 may reflect abnormal trophoblastic invasion and chronic inflammation in severe pre-eclampsia.
• CA-125 may serve as a potential biomarker for assessing pre-eclampsia severity and predicting adverse outcomes.